Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diagnosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04068077|
Recruitment Status : Recruiting
First Posted : August 28, 2019
Last Update Posted : August 28, 2019
Amyloidosis is caused by the misfolding protein accumulated in tissue, which affects the function of the organs. In addition to the primary cutaneous amyloidosis, a skin lesion may also appear in another classification - systemic amyloidosis. Physicians can confirm diagnosis of the above classification by skin biopsy.
Primary cutaneous amyloidosis is common in Asia and South America. In Taiwan, 80 people are diagnosed with primary cutaneous amyloidosis in every 100,000 people. Among the disease, macular amyloidosis and lichen amyloidosis are the most common subtypes. Primary cutaneous amyloidosis can cause severe itching, pigmentation, and skin keratosis, and further affect the social behavior of patients. The etiology of primary cutaneous amyloidosis is currently unclear, possibly due to genetic variations or viral infection. Typical primary cutaneous amyloidosis can be diagnosed by clinical manifestations, however, if the location or appearance of a lesion is atypical, the disease will be indistinguishable from other pigmented diseases, and further need a biopsy. If physicians can use a rapider and more accurate assistance tool to evaluate disease first, it will improve the accuracy of clinical diagnosis, relieve patient of suffering from biopsy, and further use medical resources more effectively.
Optical coherence tomography (OCT) is a kind of optical imaging medical system. It generates images by detecting the variations in refractive indexes of the various components in soft tissues. Apollo Medical Optics, Ltd. (AMO)'s OCT device (ApolloVue™ S100 image system, Viper1-S003) acquires real-time in vivo skin tissue tomograms with cellular resolution which provides a non-invasive, non-radioactive and rapid image acquisition.
In this study, AMO's OCT will be used to observe features in tomograms of primary cutaneous amyloidosis and that of other indistinguishable diseases, compare the correspondence of tomograms with pathological sections, induct features in tomograms specific to primary cutaneous amyloidosis and other indistinguishable diseases, and further establish an OCT database of primary cutaneous amyloidosis.
|Condition or disease||Intervention/treatment|
|Amyloidosis||Device: ApolloVue™ S100 image system, Viper1-S003|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diagnosis|
|Actual Study Start Date :||March 8, 2019|
|Estimated Primary Completion Date :||November 4, 2019|
|Estimated Study Completion Date :||November 4, 2019|
Patients with amyloidosis and other indistinguishable diseases
Device: ApolloVue™ S100 image system, Viper1-S003
The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
- Number of subjects with clear tissue characteristics of amyloidosis and/or other pigmented diseases in tomograms [ Time Frame: 1 year ]Number of subjects with clear tissue characteristics of tomograms will be compared to that with unclear tissue characteristics to identify the effect of the OCT on scanning amyloidosis and other pigmented diseases at study completion.
- Number of subjects with the distinction between skin lesion and normal skin in tomograms [ Time Frame: 1 year ]Number of subjects with the distinction between skin lesion and normal skin in tomograms will be compared to that with no distinction to verify the specific diseases that can be distinguished from normal skin by the OCT at study completion.
- Number of subjects with the distinction between amyloidosis and other pigmented diseases in tomograms [ Time Frame: 1 year ]Number of subjects with the distinction between amyloidosis and other pigmented diseases in tomograms will be compared to that with no distinction to verify the effect of the OCT on distinguishing amyloidosis from other pigmented diseases at study completion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04068077
|Contact: Hsin Cheng,, CRA||+886-2-87523198 ext email@example.com|
|Taipei Veterans General Hospital||Recruiting|
|Taipei City, Beitou District, Taiwan, 11217|
|Contact: Ding-Dar Lee, M.D., Ph. D. +886-938593530 firstname.lastname@example.org|
|Principal Investigator: Ding-Dar Lee, M.D., Ph. D.|
|Sub-Investigator: Yun-Ting Chang, M.D., Ph. D.|
|Sub-Investigator: Chih-Chiang Chen, M.D., Ph. D.|
|Principal Investigator:||Ding-Dar Lee, M.D., Ph. D.||Taipei Veterans General Hospital, Taiwan|